These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 16055332)

  • 1. 5-Substituted 4-anilinoquinazolines as potent, selective and orally active inhibitors of erbB2 receptor tyrosine kinase.
    Ballard P; Bradbury RH; Hennequin LF; Hickinson DM; Johnson PD; Kettle JG; Klinowska T; Morgentin R; Ogilvie DJ; Olivier A
    Bioorg Med Chem Lett; 2005 Oct; 15(19):4226-9. PubMed ID: 16055332
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neutral 5-substituted 4-anilinoquinazolines as potent, orally active inhibitors of erbB2 receptor tyrosine kinase.
    Ballard P; Barlaam BC; Bradbury RH; Dishington A; Hennequin LF; Hickinson DM; Hollingsworth IM; Kettle JG; Klinowska T; Ogilvie DJ; Pearson SE; Scott JS; Suleman A; Whittaker R; Williams EJ; Wood R; Wright L
    Bioorg Med Chem Lett; 2007 Nov; 17(22):6326-9. PubMed ID: 17869514
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A new series of neutral 5-substituted 4-anilinoquinazolines as potent, orally active inhibitors of erbB2 receptor tyrosine kinase.
    Barlaam B; Ballard P; Bradbury RH; Ducray R; Germain H; Hickinson DM; Hudson K; Kettle JG; Klinowska T; Magnien F; Ogilvie DJ; Olivier A; Pearson SE; Scott JS; Suleman A; Trigwell CB; Vautier M; Whittaker RD; Wood R
    Bioorg Med Chem Lett; 2008 Jan; 18(2):674-8. PubMed ID: 18061446
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibitors of epidermal growth factor receptor tyrosine kinase: Novel C-5 substituted anilinoquinazolines designed to target the ribose pocket.
    Ballard P; Bradbury RH; Harris CS; Hennequin LF; Hickinson M; Johnson PD; Kettle JG; Klinowska T; Leach AG; Morgentin R; Pass M; Ogilvie DJ; Olivier A; Warin N; Williams EJ
    Bioorg Med Chem Lett; 2006 Mar; 16(6):1633-7. PubMed ID: 16380259
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neutral 5-substituted 4-indazolylaminoquinazolines as potent, orally active inhibitors of erbB2 receptor tyrosine kinase.
    Barlaam B; Acton DG; Ballard P; Bradbury RH; Cross D; Ducray R; Germain H; Hudson K; Klinowska T; Magnien F; Ogilvie DJ; Olivier A; Ross HS; Smith R; Trigwell CB; Vautier M; Wright L
    Bioorg Med Chem Lett; 2008 Mar; 18(6):1799-803. PubMed ID: 18313293
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tyrosine kinase inhibitors. 15. 4-(Phenylamino)quinazoline and 4-(phenylamino)pyrido[d]pyrimidine acrylamides as irreversible inhibitors of the ATP binding site of the epidermal growth factor receptor.
    Smaill JB; Palmer BD; Rewcastle GW; Denny WA; McNamara DJ; Dobrusin EM; Bridges AJ; Zhou H; Showalter HD; Winters RT; Leopold WR; Fry DW; Nelson JM; Slintak V; Elliot WL; Roberts BJ; Vincent PW; Patmore SJ
    J Med Chem; 1999 May; 42(10):1803-15. PubMed ID: 10346932
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery and biological evaluation of potent dual ErbB-2/EGFR tyrosine kinase inhibitors: 6-thiazolylquinazolines.
    Gaul MD; Guo Y; Affleck K; Cockerill GS; Gilmer TM; Griffin RJ; Guntrip S; Keith BR; Knight WB; Mullin RJ; Murray DM; Rusnak DW; Smith K; Tadepalli S; Wood ER; Lackey K
    Bioorg Med Chem Lett; 2003 Feb; 13(4):637-40. PubMed ID: 12639547
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of N,1,4,4-tetramethyl-8-{[4-(4-methylpiperazin-1-yl)phenyl]amino}-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide (PHA-848125), a potent, orally available cyclin dependent kinase inhibitor.
    Brasca MG; Amboldi N; Ballinari D; Cameron A; Casale E; Cervi G; Colombo M; Colotta F; Croci V; D'Alessio R; Fiorentini F; Isacchi A; Mercurio C; Moretti W; Panzeri A; Pastori W; Pevarello P; Quartieri F; Roletto F; Traquandi G; Vianello P; Vulpetti A; Ciomei M
    J Med Chem; 2009 Aug; 52(16):5152-63. PubMed ID: 19603809
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of potent pyrazolo[4,3-h]quinazoline-3-carboxamides as multi-cyclin-dependent kinase inhibitors.
    Traquandi G; Ciomei M; Ballinari D; Casale E; Colombo N; Croci V; Fiorentini F; Isacchi A; Longo A; Mercurio C; Panzeri A; Pastori W; Pevarello P; Volpi D; Roussel P; Vulpetti A; Brasca MG
    J Med Chem; 2010 Mar; 53(5):2171-87. PubMed ID: 20141146
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel 4-anilinoquinazolines with C-6 carbon-linked side chains: synthesis and structure-activity relationship of a series of potent, orally active, EGF receptor tyrosine kinase inhibitors.
    Hennequin LF; Ballard P; Boyle FT; Delouvrié B; Ellston RP; Halsall CT; Harris CS; Hudson K; Kendrew J; Pease JE; Ross HS; Smith P; Vincent JL
    Bioorg Med Chem Lett; 2006 May; 16(10):2672-6. PubMed ID: 16516473
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis and biological evaluation of substituted 6-alkynyl-4-anilinoquinazoline derivatives as potent EGFR inhibitors.
    Liu LT; Yuan TT; Liu HH; Chen SF; Wu YT
    Bioorg Med Chem Lett; 2007 Nov; 17(22):6373-7. PubMed ID: 17889528
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification and optimisation of a series of substituted 5-(1H-pyrazol-3-yl)-thiophene-2-hydroxamic acids as potent histone deacetylase (HDAC) inhibitors.
    Price S; Bordogna W; Bull RJ; Clark DE; Crackett PH; Dyke HJ; Gill M; Harris NV; Gorski J; Lloyd J; Lockey PM; Mullett J; Roach AG; Roussel F; White AB
    Bioorg Med Chem Lett; 2007 Jan; 17(2):370-5. PubMed ID: 17095213
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tyrosine kinase inhibitors. 19. 6-Alkynamides of 4-anilinoquinazolines and 4-anilinopyrido[3,4-d]pyrimidines as irreversible inhibitors of the erbB family of tyrosine kinase receptors.
    Klutchko SR; Zhou H; Winters RT; Tran TP; Bridges AJ; Althaus IW; Amato DM; Elliott WL; Ellis PA; Meade MA; Roberts BJ; Fry DW; Gonzales AJ; Harvey PJ; Nelson JM; Sherwood V; Han HK; Pace G; Smaill JB; Denny WA; Showalter HD
    J Med Chem; 2006 Feb; 49(4):1475-85. PubMed ID: 16480284
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel 4-anilinoquinazolines with C-7 basic side chains: design and structure activity relationship of a series of potent, orally active, VEGF receptor tyrosine kinase inhibitors.
    Hennequin LF; Stokes ES; Thomas AP; Johnstone C; Plé PA; Ogilvie DJ; Dukes M; Wedge SR; Kendrew J; Curwen JO
    J Med Chem; 2002 Mar; 45(6):1300-12. PubMed ID: 11881999
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 1-Acyl-1H-[1,2,4]triazole-3,5-diamine analogues as novel and potent anticancer cyclin-dependent kinase inhibitors: synthesis and evaluation of biological activities.
    Lin R; Connolly PJ; Huang S; Wetter SK; Lu Y; Murray WV; Emanuel SL; Gruninger RH; Fuentes-Pesquera AR; Rugg CA; Middleton SA; Jolliffe LK
    J Med Chem; 2005 Jun; 48(13):4208-11. PubMed ID: 15974571
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The discovery of highly selective erbB2 (Her2) inhibitors for the treatment of cancer.
    Lippa B; Kauffman GS; Arcari J; Kwan T; Chen J; Hungerford W; Bhattacharya S; Zhao X; Williams C; Xiao J; Pustilnik L; Su C; Moyer JD; Ma L; Campbell M; Steyn S
    Bioorg Med Chem Lett; 2007 Jun; 17(11):3081-6. PubMed ID: 17398092
    [TBL] [Abstract][Full Text] [Related]  

  • 17. N-(5-chloro-1,3-benzodioxol-4-yl)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5- (tetrahydro-2H-pyran-4-yloxy)quinazolin-4-amine, a novel, highly selective, orally available, dual-specific c-Src/Abl kinase inhibitor.
    Hennequin LF; Allen J; Breed J; Curwen J; Fennell M; Green TP; Lambert-van der Brempt C; Morgentin R; Norman RA; Olivier A; Otterbein L; Plé PA; Warin N; Costello G
    J Med Chem; 2006 Nov; 49(22):6465-88. PubMed ID: 17064066
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NMS-P937, a 4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline derivative as potent and selective Polo-like kinase 1 inhibitor.
    Beria I; Bossi RT; Brasca MG; Caruso M; Ceccarelli W; Fachin G; Fasolini M; Forte B; Fiorentini F; Pesenti E; Pezzetta D; Posteri H; Scolaro A; Re Depaolini S; Valsasina B
    Bioorg Med Chem Lett; 2011 May; 21(10):2969-74. PubMed ID: 21470862
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cellular and in vivo activity of JNJ-28871063, a nonquinazoline pan-ErbB kinase inhibitor that crosses the blood-brain barrier and displays efficacy against intracranial tumors.
    Emanuel SL; Hughes TV; Adams M; Rugg CA; Fuentes-Pesquera A; Connolly PJ; Pandey N; Moreno-Mazza S; Butler J; Borowski V; Middleton SA; Gruninger RH; Story JR; Napier C; Hollister B; Greenberger LM
    Mol Pharmacol; 2008 Feb; 73(2):338-48. PubMed ID: 17975007
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis and biological evaluation of crown ether fused quinazoline analogues as potent EGFR inhibitors.
    Hu S; Xie G; Zhang DX; Davis C; Long W; Hu Y; Wang F; Kang X; Tan F; Ding L; Wang Y
    Bioorg Med Chem Lett; 2012 Oct; 22(19):6301-5. PubMed ID: 22959248
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.